Defining the pharmacokinetic/pharmacodynamic index of piperacillin/tazobactam within a hollow-fibre infection model to determine target attainment in intensive care patients.
Suzanne A M WenkerNajla AlabdulkarimJohn B ReadmanElise M A SlobGiovanni SattaShanom AliNishma GadherRob ShulmanJoseph F StandingPublished in: JAC-antimicrobial resistance (2024)
kill. Doses to achieve this target should be considered when treating patients in ICU.